On September 1, 2026 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), reported that it has closed on a financing of $16.5 million in gross proceeds, with Paulson Investment Company acting as placement agent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The demand from investors reflects confidence in CytoDyn’s clinical progress and its versatile development strategy as the Company continues to advance leronlimab across its oncology programs.

"The successful execution of this financing demonstrates continued and strong investor support for our clinical strategy and the long-term potential of leronlimab," said Robert E. Hoffman, CFO of CytoDyn. "We are encouraged by the continued commitment of our existing investors, as well as the strong engagement from new investors, which we believe underscores growing interest in leronlimab’s potential in immuno-oncology. With this financing expected to fund operations into the second half of 2027, we are well positioned to focus on clinical execution and the pursuit of strategic priorities that we believe will create meaningful long-term value for our shareholders."

Net proceeds from the financing are expected to be used primarily to advance CytoDyn’s clinical development programs, including ongoing and planned clinical trials, regulatory activities and data analysis. The Company may also use a portion of the proceeds to support manufacturing readiness, regulatory and compliance infrastructure, and general working capital.

For additional information on the Company’s historical financing activities, including key terms and conditions of related agreements, please refer to CytoDyn’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K filed on August 31, 2026.

(Press release, CytoDyn, SEP 1, 2026, View Source [SID1234670484])

On September 1, 2026 CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, reported that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 21st Annual Healthcare Conference
Date: Wednesday, September 9, 2026
Time: 12:45pm EDT
Webcast: Click here

A replay of the fireside chat will also be available in the "Presentations and Events" page on the investor relations portion of the Company’s website at: www.cormedix.com

(Press release, CorMedix, SEP 1, 2026, View Source [SID1234670482])

On September 1, 2026 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, reported that it will participate in the upcoming investor conferences :

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 21st Annual Healthcare Conference – Boston, MA

September 10, 2026

Baird 2026 Global Healthcare Conference – New York

September 15, 2026

Company presentation at 12:50 – 1:20 p.m. ET

Fall Focus: Barclays Biotech 1×1 Day – New York

October 6, 2026

Stifel 2026 Healthcare Conference – New York

November 10-12, 2026

Jefferies Global Healthcare Conference – London

November 16-19, 2026

Cellectis’ management team will be available for meetings with investors throughout these conferences. To arrange a meeting, please contact the respective conference representatives or Cellectis Investor Relations at [email protected]

Any available webcast will be posted to the Company’s website at View Source

(Press release, Cellectis, SEP 1, 2026, View Source [SID1234670481])

On September 1, 2026 Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, reported that it has executed a research collaboration and option agreement with the Zucker Institute (the commercialisation entity for the Medical University of South Carolina – MUSC). Under the agreement, the parties will explore Cartherics’ iPSC-derived chimeric antigen receptor natural killer (CAR-NK) platform in combination with a novel anti-tissue factor antibody developed by researchers at MUSC and the Regina Elena National Cancer Institute for potential applications in cancer and endometriosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tissue factor (TF) is a coagulation factor that is highly expressed across a broad range of solid tumours, where it plays a critical role in tumour progression, angiogenesis, invasion, and metastasis. TF is a clinically validated oncology target, with the recent FDA approval of a TF-targeting antibody-drug conjugate (ADC) for the treatment of cervical cancer[1].

Emerging research has also identified aberrant TF expression in endometriosis, highlighting the potential of TF-targeted therapies beyond oncology and opening a potential new therapeutic approach for this chronic and debilitating disease.

Assoc Prof John Wrangle, MD MPH, of MUSC, and Dr Alessandra Metelli, PhD, of the Regina Elena National Cancer Institute in Italy, developed a highly specific anti-TF antibody designed to provide an improved safety profile compared with currently available anti-TF antibodies. Assoc Prof Wrangle, Dr. Metelli, and their collaborators have demonstrated the potential of this antibody across multiple therapeutic applications.

Assoc Prof Wrangle said, "Tissue factor is an incredibly important and under explored target in cancer therapeutics. We now know that tissue factor is not only present on a huge number of cancers including ovarian cancer, but also is integral to how cancers grow, survive, and resist our best therapies. The purpose of Dr. Metelli and my science is to learn how to safely kill cancer cells that sustain themselves with tissue factor, and grateful to be partnering with Cartherics to utilize their incredible approach to off the shelf cellular therapy."

Under this agreement, Cartherics will evaluate the incorporation of this novel antibody technology into next-generation TF-targeting CAR NK cell therapies for solid tumours, including triple-negative breast cancer, while also exploring potential applications in endometriosis.

The TF CAR-NK cell products will be evaluated for both in vitro and in vivo efficacy using relevant human cancer and endometriosis models.

Cartherics’ Chief Scientific Officer, Dr Walid Azar commented: "We are delighted to incorporate this innovative antibody technology into Cartherics’ established iPSC-derived CAR-NK cell platform. We believe this collaboration provides an exciting opportunity to develop the next-generation cell therapies for patients with limited treatment options and look forward to working closely with Assoc Prof Wrangle and Dr Metelli, whose expertise in tissue factor biology and their technology will be instrumental in advancing our program."

(Press release, Cartherics, SEP 1, 2026, View Source [SID1234670480])

On September 1, 2026 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, reported that it is advancing the potential application of its CyPath Lung test for surveillance of lung cancer patients who have completed curative-intent treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lung cancer recurrence remains a significant clinical challenge. According to the American Cancer Society, there were more than 680,000 Americans living with a prior lung cancer diagnosis as of January 1, 2025.1 The National Cancer Institute estimates that another 230,000 patients will be diagnosed with lung cancer in 2026.

"For patients who have completed cancer treatment, the discovery of a new pulmonary nodule can create tremendous uncertainty. Imaging alone cannot tell us if it is recurrent cancer, a new cancer, or benign post-treatment changes including fibrosis, scarring, and treatment-related inflammation," said Vijay Gunuganti, MD, an oncologist with Texas Oncology, a physician-led practice in San Antonio, Texas. "CyPath Lung can provide additional information without immediately subjecting the patient to an invasive procedure. The test’s binary result – unlikely or likely malignancy – can help us determine which patients need closer investigation and which patients may be appropriate for continued surveillance."

"CyPath Lung has demonstrated its ability to detect early-stage lung cancer in clinical trials and clinical practice," said Maria Zannes, President and CEO of bioAffinity Technologies. "As our commercial experience with CyPath Lung grows, we are examining how our noninvasive approach may provide value throughout the patient’s lung cancer journey. We believe surveillance after cancer treatment has the potential to lead to earlier intervention and could be an important complement to early detection for newly diagnosed patients in terms of improving patient outcomes."

Even when patients have no evidence of disease (NED) following surgery or radiation, published studies report recurrence rates of approximately 20% to 55% for non-small cell lung cancer (NSCLC), depending on stage, treatment and other factors.2 The American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) recommends surveillance imaging every six months for two years following curative-intent treatment of stage I–III NSCLC, followed by annual low-dose CT to monitor for new primary lung cancers.3

"Finishing curative-intent treatment is not the end of cancer care. As survival rates continue to improve and more people with a cancer diagnosis are living longer lives, survivorship care is increasingly important. That means proactive follow-up for recurrence, screening for new cancers and monitoring for long-term treatment effects," said Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies." CyPath Lung complements CT surveillance by providing actionable information that helps physicians evaluate new or changing pulmonary nodules identified by imaging."

The potential role of CyPath Lung in recurrence surveillance builds on the test’s ability to analyze the lung microenvironment in real time. Drawing on three years of commercial experience, CyPath Lung has shown promising clinical performance in helping physicians stratify malignancy risk and guide patient management, including clinical case studies that illustrate how CyPath Lung helped clarify challenging cases in which imaging findings and predictive models alone produced uncertain or conflicting assessments.

(Press release, BioAffinity Technologies, SEP 1, 2026, View Source [SID1234670479])